Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Neuroectodermal Tumors × Vorinostat × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasms 6 Multiple Myeloma 6 Lymphoma 6 Carcinoma, Non-Small-Cell Lung 6 Lymphoma, T-Cell, Cutaneous 4 Mycosis Fungoides 3 Sezary Syndrome 2 Recurrence 2 Lymphoproliferative Disorders 2 Lymphoma, Non-Hodgkin 2 Lymphoma, Large B-Cell, Diffuse 2 Immunoproliferative Disorders 2 Immune System Diseases 2 Vascular Diseases 1 Paraproteinemias 1 Pancreatic Neoplasms 1 Neuroectodermal Tumors 1 Neuroblastoma 1 Neoplasms, Plasma Cell 1 Neoplasms by Histologic Type 1 Myelodysplastic Syndromes 1 Mesothelioma 1 Melanoma 1 Lymphoma, T-Cell 1 Lymphoma, Mantle-Cell 1 Lymphoma, B-Cell 1 Lymphatic Diseases 1 Lung Neoplasms 1 Leukemia 1 Hodgkin Disease 1

Interventions

vorasidenib 1 repotrectinib 1 pralsetinib 1 pembrolizumab 1 pamiparib 1 Vorinostat 1 Radiation 1 Oncolytic Virotherapy 1 ONC206 1 Antibodies, Monoclonal 1 Afatinib 1 3-Iodobenzylguanidine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03561259 2023-02-16

OPTIMUM

Jubilant DraxImage Inc.

Phase 2 Unknown

Neoplasms, Neuroblastoma, Neuroectodermal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡